Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 20/20 | 0.69 |
| ▸ | MAOB | P27338 | 5/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16989651 | 1.00 | KDM1A (0.69) | KDM1AMAOBHDAC6DRD2HTR2A | |
| SCHEMBL27970680 | 0.92 | KDM1A (0.69) | KDM1AMAOBHDAC6DRD2HTR2A | |
| SCHEMBL12966204 | 0.90 | KDM1A (0.70) | KDM1AMAOBHDAC6DRD2HTR2A | |
| SCHEMBL15411555 | 0.90 | KDM1A (0.70) | KDM1AMAOBHDAC6DRD2HTR2A | |
| SCHEMBL15424989 | 0.90 | KDM1A (0.70) | KDM1AMAOBHDAC6DRD2HTR2A | |
| SCHEMBL15411553 | 0.90 | KDM1A (0.70) | KDM1AMAOBHDAC6DRD2HTR2A | |
| SCHEMBL12813799 | 0.88 | KDM1A (0.64) | KDM1AMAOBHDAC6DRD2HTR2A | |
| SCHEMBL12813798 | 0.88 | KDM1A (0.64) | KDM1AMAOBHDAC6DRD2HTR2A | |
| SCHEMBL12813629 | 0.88 | KDM1A (0.59) | KDM1AMAOBHDAC6DRD2HTR2A | |
| SCHEMBL14882091 | 0.88 | KDM1A (0.59) | KDM1AMAOBHDAC6DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155532-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210024487-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-01-28 | — | — | US | disclosed |
| US-10676457-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3626714-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Incyte Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3105226-B1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| US-9994546-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170121302-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-05-04 | — | — | US | disclosed |
| US-9493450-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150225394-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676457-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 326/4885HDAC6 264/4885 |
| US-20210024487-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 326/4885HDAC6 264/4885 |
| US-20170121302-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 326/4885HDAC6 264/4885 |
| US-11155532-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 326/4885HDAC6 264/4885 |
| US-20150225394-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 326/4885HDAC6 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.